METHODS: The clinical data of 150 PCa patients were reviewed consecutively from January 2015 to March 2020 in this study. The relationships between clinical characteristics, serum
biomarkers and bone
metastasis in PCa patients were analyzed, respectively. Multivariate logistic regression analysis was applied to identify potential markers of bone
metastasis in
prostate cancer. Receiver operating characteristic (ROC) curve was used to explore the diagnostic values of potential
biomarkers.
RESULTS: Compared with the PCa patients without bone
metastasis, the serum levels of CA-125, T-PSA, F-PSA, CYFRA21-1 and
ProGRP were significantly elevated in PCa patients with bone
metastasis. Multivariate logistic regression analysis showed that T-PSA (OR 1.014, P = 0.021), F-PSA (OR 1.124, P = 0.016) and
Pro-gastrin-releasing
peptide (
ProGRP) (OR 1.057, P = 0.026) were significantly associated with the bone
metastasis of PCa patients. ROC curves indicated that T-PSA, F-PSA and
ProGRP could effectively discriminate bone
metastasis from non-bone
metastasis PCa patients, and the AUCs (area under the curves) were 0.885, 0.919 and 0.752, respectively. According to the Youden index, the cut-off values of T-PSA, F-PSA and
ProGRP were defined as 56.50 ng/ml, 6.96 ng/ml and 31.60 pg/ml, respectively. T-PSA, F-PSA and
ProGRP produced a sensitivity of 78.30%, 81.70% and 61.70%, a specificity of 93.30%, 88.90% and 82.20%, respectively. The AUC for the combination of T-PSA, F-PSA with
ProGRP was 0.941 with 90.00% sensitivity, much better than that of any single
biomarker or two
biomarkers combinate.
CONCLUSIONS: